Alarm vs miscellaneous treatments
Proportion of children adverse events · children with nocturnal enuresis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
4,720 questions · 15,377 findings · 900 reviews
No studies found 3,865 · 25.1%GRADE not reported 2,291 · 14.9%Very low 3,875 · 25.2%Low 3,287 · 21.4%Moderate 1,681 · 10.9%High 378 · 2.5%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Alarm plus other intervention vs other interventions
Mean number of wet nights a week · children with nocturnal enuresis
2 findings from 1 review
- no estimate extracted1 study · 22 participantsVery low
- no estimate extracted2 studies · 156 participantsLow
Alarm plus other intervention vs other interventions
Proportion of children achieving 14 consecutive dry nights by the end of treatment · children with nocturnal enuresis
It is very uncertain whether alarm plus other intervention changes proportion of children achieving 14 consecutive dry nights by the… compared with other intervention (very low certainty).
3 findings from 1 review
- RR 3 [0.73, 12.27]1 study · 22 participantsVery low
- RR 3.79 [1.85, 7.77]1 study · 80 participantsLow
- RR 1.32 [1.08, 1.62]5 studies · 359 participantsLow
Alarm vs placebo drug
Mean number of wet nights a week · children with nocturnal enuresis
1 finding from 1 review
- no estimate extracted1 study · 47 participantsVery low
Alarm plus other intervention vs other interventions
Proportion of children dry at · children with nocturnal enuresis
Alarm plus other intervention showed no clear difference in proportion of children dry at compared with other intervention (low certainty).
2 findings from 1 review
- RR 0.56 [0.15, 2.12]1 study · 80 participantsLow
- RR 2.33 [1.26, 4.29]2 studies · 161 participantsLow
Alarm plus other intervention vs other interventions
Proportion of children with adverse events · children with nocturnal enuresis
1 finding from 1 review
- no estimate extracted1 study · 1 participantsGRADE not reported
Alarm vs placebo drug
Proportion of children achieving 14 consecutive dry nights by the end of treatment · children with nocturnal enuresis
Alarm may leads to higher proportion of children achieving 14 consecutive dry nights by the… compared with placebo drug (low certainty).
1 finding from 1 review
- RR 1.59 [1.16, 2.17]2 studies · 181 participantsLow
Alarm vs placebo drug
Proportion of children dry at · children with nocturnal enuresis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Alarm vs placebo drug
Proportion of children with adverse events · children with nocturnal enuresis
1 finding from 1 review
- no estimate extracted2 studies · 2 participantsGRADE not reported
Intervention not reported
Death at one year · adults with renal vasculitis
The intervention showed no clear difference in death at one year (low certainty).
1 finding from 1 review
- RR 1.04 [0.57, 1.92]5 studies · 267 participantsLow
Pulse cyclophosphamide vs continuous cyclophosphamide
Dialysis · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in dialysis at end of study compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
- RR 1.9 [0.92, 3.91]4 studies · 245 participantsLow
Pulse cyclophosphamide vs continuous cyclophosphamide
Remission · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in remission at 6 months compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
- RR 1.03 [0.93, 1.13]2 studies · 176 participantsLow
Pulse cyclophosphamide vs continuous cyclophosphamide
Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment] · adults with renal vasculitis
Pulse cyclophosphamide may leads to higher relapse at the end of compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
- RR 1.79 [1.11, 2.87]4 studies · 235 participantsLow
Pulse cyclophosphamide vs continuous cyclophosphamide
Adverse events ‐ treatment failure · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in adverse events ‐ treatment failure compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
- RR 1.36 [0.115, 12.56]2 studies · 82 participantsLow
Pulse cyclophosphamide vs continuous cyclophosphamide
Serious infections · adults with renal vasculitis
Pulse cyclophosphamide showed no clear difference in serious infections compared with continuous cyclophosphamide (low certainty).
1 finding from 1 review
- RR 0.71 [0.38, 1.33]4 studies · 278 participantsLow
Rituximab vs cyclophosphamide
Death at 6 months · adults with renal vasculitis
Rituximab showed no clear difference in death at 6 months compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
- RR 1 [0.21, 4.7]2 studies · 241 participantsModerate
Rituximab vs cyclophosphamide
Kidney function · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Rituximab vs cyclophosphamide
Dialysis · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Rituximab vs cyclophosphamide
Remission · adults with renal vasculitis
Rituximab showed no clear difference in remission at 6 months compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
- RR 1.02 [0.79, 1.32]2 studies · 236 participantsModerate
Rituximab vs cyclophosphamide
Relapse · adults with renal vasculitis
Rituximab showed no clear difference in relapse at 12 months compared with cyclophosphamide (low certainty).
1 finding from 1 review
- RR 1.43 [0.18, 11.31]1 study · 38 participantsLow